Neumora Therapeutics, Inc.
NMRA
$1.84
-$0.13-6.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 60.09M | 63.29M | 67.13M | 67.01M | 62.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 236.16M | 240.60M | 264.54M | 274.33M | 263.46M |
| Operating Income | -236.16M | -240.60M | -264.54M | -274.33M | -263.46M |
| Income Before Tax | -236.80M | -236.17M | -251.91M | -257.78M | -243.61M |
| Income Tax Expenses | 130.00K | 130.00K | 183.00K | 283.00K | 178.00K |
| Earnings from Continuing Operations | -236.93 | -236.30 | -252.09 | -258.06 | -243.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -236.93M | -236.30M | -252.09M | -258.06M | -243.79M |
| EBIT | -236.16M | -240.60M | -264.54M | -274.33M | -263.46M |
| EBITDA | -235.95M | -240.24M | -264.06M | -273.70M | -262.83M |
| EPS Basic | -1.45 | -1.46 | -1.57 | -1.61 | -1.53 |
| Normalized Basic EPS | -0.89 | -0.89 | -0.98 | -1.01 | -0.96 |
| EPS Diluted | -1.45 | -1.46 | -1.57 | -1.61 | -1.53 |
| Normalized Diluted EPS | -0.89 | -0.89 | -0.98 | -1.01 | -0.96 |
| Average Basic Shares Outstanding | 653.50M | 645.96M | 643.70M | 641.00M | 637.49M |
| Average Diluted Shares Outstanding | 653.50M | 645.96M | 643.70M | 641.00M | 637.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |